Cellectis Highlights Allogene's Pivotal Trial Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy CLLS?
Source: Newsfilter
- Clinical Trial Progress: Allogene Therapeutics' interim Event-Free Survival analysis from the ALPHA3 trial reveals that 58.3% of patients in the cema-cel arm achieved minimal residual disease (MRD) negativity, compared to 16.7% in the observation arm, indicating significant potential clinical benefits for this therapy in treating large B-cell lymphoma.
- Safety Assessment: As of the data cutoff, cema-cel treatment was generally well-tolerated, with 10 out of 12 patients managed in an outpatient setting post-infusion and no cases of cytokine release syndrome or other serious adverse events, demonstrating its safety in clinical applications.
- Market Potential: Cellectis is eligible for up to $340 million in development and sales milestone payments under the Servier Agreement, along with low double-digit royalties on net sales of cema-cel, highlighting its significant position in the cell therapy market.
- Future Outlook: Allogene anticipates completing study accrual by the end of 2027 and plans an interim Event-Free Survival analysis in mid-2027, with positive results potentially supporting a Biologics License Application (BLA), further advancing the commercialization of cema-cel.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLLS
Wall Street analysts forecast CLLS stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 4.160
Low
4.00
Averages
7.00
High
9.00
Current: 4.160
Low
4.00
Averages
7.00
High
9.00
About CLLS
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cellectis Highlights Allogene's Pivotal Trial Progress
- Clinical Trial Progress: Allogene Therapeutics' interim Event-Free Survival analysis from the ALPHA3 trial reveals that 58.3% of patients in the cema-cel arm achieved minimal residual disease (MRD) negativity, compared to 16.7% in the observation arm, indicating significant potential clinical benefits for this therapy in treating large B-cell lymphoma.
- Safety Assessment: As of the data cutoff, cema-cel treatment was generally well-tolerated, with 10 out of 12 patients managed in an outpatient setting post-infusion and no cases of cytokine release syndrome or other serious adverse events, demonstrating its safety in clinical applications.
- Market Potential: Cellectis is eligible for up to $340 million in development and sales milestone payments under the Servier Agreement, along with low double-digit royalties on net sales of cema-cel, highlighting its significant position in the cell therapy market.
- Future Outlook: Allogene anticipates completing study accrual by the end of 2027 and plans an interim Event-Free Survival analysis in mid-2027, with positive results potentially supporting a Biologics License Application (BLA), further advancing the commercialization of cema-cel.
See More
Cellectis SA Reports 2025 Financial Results and Clinical Updates
- Financial Overview: As of December 31, 2025, Cellectis SA reported cash and fixed-term deposits of $211 million, down from $264 million in 2024, indicating potential pressure on funding that could impact future R&D investments.
- Clinical Trial Progress: The Lasm cell candidate achieved a 100% overall response rate at the recommended Phase 2 dose in relapsed or refractory B-cell acute lymphoblastic leukemia, marking a significant breakthrough that may enhance the company's competitive position in the CAR T therapy market.
- Eisel Candidate Performance: Eisel demonstrated an 88% overall response rate and a 63% complete response rate in non-Hodgkin's lymphoma patients, providing encouraging preliminary results that could bolster investor confidence and support subsequent clinical trials.
- Market Challenges and Opportunities: Despite facing significant challenges in the biotech sector, Cellectis maintains strong partnerships with Allogene and Iovance, ensuring ongoing validation of its gene editing platform, with a potential BLA submission for Lasm cell expected in the second half of 2028, further expanding market opportunities.
See More
Cellectis to Announce Q4 Earnings on March 19
- Earnings Announcement: Cellectis is set to release its Q4 earnings on March 19 after market close, with investors keenly awaiting insights into its performance and future outlook.
- Earnings Expectations: The consensus EPS estimate stands at -$0.10, reflecting a 37.5% year-over-year improvement, indicating the company's efforts to enhance profitability.
- Revenue Forecast: The consensus revenue estimate is $12.47 million, representing a significant 62.5% year-over-year decline, highlighting the market challenges and sales pressures the company is currently facing.
- Historical Performance Review: Over the past year, Cellectis has beaten EPS estimates 50% of the time and revenue estimates 25% of the time, underscoring the uncertainty surrounding the company's earnings forecasts.
See More
Cellectis Initiates Pivotal Trials for Lasme-cel and Eti-cel, 2026 Outlook Positive
- Clinical Trial Progress: Cellectis initiated the pivotal Phase 2 BALLI-01 trial for lasme-cel in October 2025, with the first interim analysis expected in Q4 2026 involving 40 participants, showcasing the company's strong growth potential in tumor immunotherapy.
- Impressive Efficacy Data: Lasme-cel achieved a 100% overall response rate and a 56% complete remission rate in the target Phase 2 population, with 80% of patients reaching minimal residual disease-negative status, indicating significant efficacy in treating relapsed acute lymphoblastic leukemia (B-ALL).
- Deepening Strategic Partnerships: Cellectis is advancing its collaboration with AstraZeneca to develop up to 10 novel cell and gene therapy products addressing high unmet medical needs, further solidifying its leadership position in the biotechnology sector.
- Sufficient Cash Runway: Cellectis believes its cash and cash equivalents will fund operations into H2 2027, ensuring continued progress in critical clinical trials and strategic investments.
See More
Autolus Evaluates Cellares' Automated Platform for Manufacturing Expansion
- Manufacturing Capability Assessment: Autolus will evaluate Cellares' Cell Shuttle platform to enhance its commercial manufacturing operations at the Nucleus facility in Stevenage, UK, which is expected to improve production efficiency and reduce costs.
- High-Throughput Production: Cellares' platform can process up to 16 patient batches simultaneously, delivering up to 10-fold higher throughput than conventional cell therapy manufacturing facilities, potentially significantly enhancing Autolus' market competitiveness.
- Exploration of New Indications: Autolus is assessing its AUCATZYL® therapy for indications beyond acute lymphoblastic leukemia, and successful expansion could lead to increased demand for manufacturing capacity.
- Strategic Partnership Outlook: The integration of Cellares' technology with Autolus' existing manufacturing foundation may provide a capital-efficient solution for future expansion, addressing the growing patient demand.
See More
Cellectis SA Receives Buy Rating with $9 Price Target from Clear Street
- Analyst Rating Change: Clear Street analyst Bill Maughan initiated coverage on Cellectis SA (NASDAQ:CLLS) with a Buy rating and a price target of $9, representing a potential upside of 91% from its closing price of $4.69 on Monday, indicating optimistic market expectations for its future growth.
- Levi Strauss Rating Upgrade: Raymond James analyst Rick Patel initiated coverage on Levi Strauss & Co. (NYSE:LEVI) with an Outperform rating and a price target of $26, while the stock closed at $21.23, suggesting analysts' confidence in its future performance, which may attract more investor interest.
- Spruce Biosciences Positive Outlook: Oppenheimer analyst Leland Gershell initiated coverage on Spruce Biosciences, Inc. (NASDAQ:SPRB) with an Outperform rating and a price target of $283, compared to its closing price of $82.82 on Monday, indicating a potential upside of over 240%, reflecting strong market confidence in its product pipeline.
- Septerna, Inc. Buy Rating: Jones Trading analyst Catherine Novack initiated coverage on Septerna, Inc. (NASDAQ:SEPN) with a Buy rating and a price target of $43, while the stock closed at $29.47, indicating an upside of approximately 46%, which may attract investors seeking growth opportunities.
See More
Cellectis Highlights Allogene's Pivotal Trial Progress
- Clinical Trial Progress: Allogene Therapeutics' interim Event-Free Survival analysis from the ALPHA3 trial reveals that 58.3% of patients in the cema-cel arm achieved minimal residual disease (MRD) negativity, compared to 16.7% in the observation arm, indicating significant potential clinical benefits for this therapy in treating large B-cell lymphoma.
- Safety Assessment: As of the data cutoff, cema-cel treatment was generally well-tolerated, with 10 out of 12 patients managed in an outpatient setting post-infusion and no cases of cytokine release syndrome or other serious adverse events, demonstrating its safety in clinical applications.
- Market Potential: Cellectis is eligible for up to $340 million in development and sales milestone payments under the Servier Agreement, along with low double-digit royalties on net sales of cema-cel, highlighting its significant position in the cell therapy market.
- Future Outlook: Allogene anticipates completing study accrual by the end of 2027 and plans an interim Event-Free Survival analysis in mid-2027, with positive results potentially supporting a Biologics License Application (BLA), further advancing the commercialization of cema-cel.
See More
Cellectis SA Reports 2025 Financial Results and Clinical Updates
- Financial Overview: As of December 31, 2025, Cellectis SA reported cash and fixed-term deposits of $211 million, down from $264 million in 2024, indicating potential pressure on funding that could impact future R&D investments.
- Clinical Trial Progress: The Lasm cell candidate achieved a 100% overall response rate at the recommended Phase 2 dose in relapsed or refractory B-cell acute lymphoblastic leukemia, marking a significant breakthrough that may enhance the company's competitive position in the CAR T therapy market.
- Eisel Candidate Performance: Eisel demonstrated an 88% overall response rate and a 63% complete response rate in non-Hodgkin's lymphoma patients, providing encouraging preliminary results that could bolster investor confidence and support subsequent clinical trials.
- Market Challenges and Opportunities: Despite facing significant challenges in the biotech sector, Cellectis maintains strong partnerships with Allogene and Iovance, ensuring ongoing validation of its gene editing platform, with a potential BLA submission for Lasm cell expected in the second half of 2028, further expanding market opportunities.
See More
Cellectis to Announce Q4 Earnings on March 19
- Earnings Announcement: Cellectis is set to release its Q4 earnings on March 19 after market close, with investors keenly awaiting insights into its performance and future outlook.
- Earnings Expectations: The consensus EPS estimate stands at -$0.10, reflecting a 37.5% year-over-year improvement, indicating the company's efforts to enhance profitability.
- Revenue Forecast: The consensus revenue estimate is $12.47 million, representing a significant 62.5% year-over-year decline, highlighting the market challenges and sales pressures the company is currently facing.
- Historical Performance Review: Over the past year, Cellectis has beaten EPS estimates 50% of the time and revenue estimates 25% of the time, underscoring the uncertainty surrounding the company's earnings forecasts.
See More
Cellectis Initiates Pivotal Trials for Lasme-cel and Eti-cel, 2026 Outlook Positive
- Clinical Trial Progress: Cellectis initiated the pivotal Phase 2 BALLI-01 trial for lasme-cel in October 2025, with the first interim analysis expected in Q4 2026 involving 40 participants, showcasing the company's strong growth potential in tumor immunotherapy.
- Impressive Efficacy Data: Lasme-cel achieved a 100% overall response rate and a 56% complete remission rate in the target Phase 2 population, with 80% of patients reaching minimal residual disease-negative status, indicating significant efficacy in treating relapsed acute lymphoblastic leukemia (B-ALL).
- Deepening Strategic Partnerships: Cellectis is advancing its collaboration with AstraZeneca to develop up to 10 novel cell and gene therapy products addressing high unmet medical needs, further solidifying its leadership position in the biotechnology sector.
- Sufficient Cash Runway: Cellectis believes its cash and cash equivalents will fund operations into H2 2027, ensuring continued progress in critical clinical trials and strategic investments.
See More
Autolus Evaluates Cellares' Automated Platform for Manufacturing Expansion
- Manufacturing Capability Assessment: Autolus will evaluate Cellares' Cell Shuttle platform to enhance its commercial manufacturing operations at the Nucleus facility in Stevenage, UK, which is expected to improve production efficiency and reduce costs.
- High-Throughput Production: Cellares' platform can process up to 16 patient batches simultaneously, delivering up to 10-fold higher throughput than conventional cell therapy manufacturing facilities, potentially significantly enhancing Autolus' market competitiveness.
- Exploration of New Indications: Autolus is assessing its AUCATZYL® therapy for indications beyond acute lymphoblastic leukemia, and successful expansion could lead to increased demand for manufacturing capacity.
- Strategic Partnership Outlook: The integration of Cellares' technology with Autolus' existing manufacturing foundation may provide a capital-efficient solution for future expansion, addressing the growing patient demand.
See More
Cellectis SA Receives Buy Rating with $9 Price Target from Clear Street
- Analyst Rating Change: Clear Street analyst Bill Maughan initiated coverage on Cellectis SA (NASDAQ:CLLS) with a Buy rating and a price target of $9, representing a potential upside of 91% from its closing price of $4.69 on Monday, indicating optimistic market expectations for its future growth.
- Levi Strauss Rating Upgrade: Raymond James analyst Rick Patel initiated coverage on Levi Strauss & Co. (NYSE:LEVI) with an Outperform rating and a price target of $26, while the stock closed at $21.23, suggesting analysts' confidence in its future performance, which may attract more investor interest.
- Spruce Biosciences Positive Outlook: Oppenheimer analyst Leland Gershell initiated coverage on Spruce Biosciences, Inc. (NASDAQ:SPRB) with an Outperform rating and a price target of $283, compared to its closing price of $82.82 on Monday, indicating a potential upside of over 240%, reflecting strong market confidence in its product pipeline.
- Septerna, Inc. Buy Rating: Jones Trading analyst Catherine Novack initiated coverage on Septerna, Inc. (NASDAQ:SEPN) with a Buy rating and a price target of $43, while the stock closed at $29.47, indicating an upside of approximately 46%, which may attract investors seeking growth opportunities.
See More
